EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

Principal Investigator

Garrett Wasp

Study Number

STUDY02002309

Summary

Strass-2 is a study for patients with a rare type of cancer, retroperitoneal sarcoma. This study aims to determine if it is possible to reduce the chance of the cancer returning or spreading. Patients will be randomized to the current standard approach of surgery to remove the cancer 4 weeks after joining the study or 9 weeks of Chemotherapy followed by surgery 3-6 weeks following. The study expects to enroll 250 patients, 125 patients to each treatment. DH expects to enroll 6 patients. The study will follow participants care for the remainder of life.

Phase

III

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms